Mediolanum Farmaceutici, a pharmaceutical company founded by the Del Bono family, has sold to Ardian the control of Neopharmed Gentili, a Milan-based company specializing in the development, production and marketing in Italy of high therapeutic value solutions in vascular, cardio-metabolic, respiratory and antibiotic areas and over-the-counter drugs (see here the press release). Mediolanum Farmaceutici remains a member of Neopharmed Gentili with a minority shareholding and Alessandro Del Bono will hold the position of chairman and chief executive officer of the company.
A deal in the sphere of Mediolanum Farmaceutici was expected by the market. Last October Ardian was said to be in talks with the company as a favourite financial partner that could support the new phase of development of the company (see here a previous post by BeBeez).
Ardian was supported by m&a advisro Rothschild, by Bain for the commercial due diligence, by PwC for the financial due diligence, by Gitti & Partners on the tax front and by Giovannelli e Associati and Gattai, Minoli, Agostinelli & Partners law firms Mediolanum Farmaceutici was assisted by Four Partners (m&a) and NCTM as for the legal issues.
Neopharmed Gentili was born in 2011 following the merger between Gentili srl, purchased by Mediolanum Farmaceutici in 2009, and Neopharmed srl, acquired in 2010. Today it represents the core of Mediolanum Farmaceutici’s business, given that Neopharmed Gentili closed 2017 with sales 192 million euros against 205.8 millions of consolidated net revenues of the entire group Mediolanum Farmaceutici, with an ebitda of 51.5 millions and a net financial debt of just 9.1 millions (see here an analysis by Leanus, after free registration and login).
“The acquisition plan carried out by Neopharmed Gentili, up to now, has allowed us to significantly increase its market share, offer products and strengthen the top-line, further expanding its share of proprietary products”. Now, explained Mr. Del Bono, the operation with Ardian “will allow the company to accelerate its development and to aim at new acquisitions, strengthening its presence in strategic areas of the pharmaceutical sector, and, last but not least, to protect employment in our country”.
Last year Mediolanum Farmaceutici acquired the Italian subsidiary of the Belgian company Therabel Gienne Pharma, signed the partnership between Levante pharma (a company of the Mediolanum Farmaceutici group) and Teva Pharmaceutical, has relaunched the Istituto Gentili, totally dedicated to oncology. Still in the field of oncology, Mediolanum Biosciences was founded in 2017 with the creation of two new business units in France and Germany dedicated to the promotion of a new cancer therapy.